Retifanlimab-dlwr demonstrates 11-month OS difference for anal cancer patients in phase III trial

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Exploratory analyses of the POTOMAC phase III trial showed adding one year of treatment with AstraZeneca’s Imfinzi (durvalumab) to BCG induction and maintenance therapy reduced the number of high-risk disease recurrences within the first year, with fewer BCG-unresponsive recurrences in patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer compared to BCG treatment alone.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Perioperative Imfinzi + neoadjuvant EV improved EFS and OS in muscle-invasive bladder cancer, phase III VOLGA trial shows

High-level results from a planned interim analysis of the VOLGA phase III trial showed perioperative treatment with Imfinzi (durvalumab) in combination with neoadjuvant enfortumab vedotin demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survival in patients with muscle-invasive bladder cancer versus standard of care.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Phase III trial of sacituzumab tirumotecan met primary endpoints in advanced or recurrent endometrial cancer

The phase III TroFuse-005 trial evaluating sacituzumab tirumotecan, an investigational TROP2-directed antibody-drug conjugate, met its primary endpoints of overall survival and progression-free survival in certain patients with advanced or recurrent endometrial cancer.

May 22, 2026

Vol.52 No.20

In Brief

Mount Sinai and Cancer Hope Network launch peer support program to help patients navigate treatment, survivorship, and clinical trials

The Mount Sinai Tisch Cancer Center has entered a partnership with Cancer Hope Network to launch Peer Access to Trials, Hope and Support, a peer-to-peer program that gives patients and caregivers access to one-on-one peer mentorship from trained volunteers who have faced cancer themselves, either as survivors or caregivers.

May 15, 2026

Vol.52 No.19

In Brief

LSU LCMC Health cancer center strengthens cancer clinical trials infrastructure to expand access across Louisiana

The LSU LCMC Health Cancer Center expanded its Cancer Clinical Trials Office.

May 15, 2026

Vol.52 No.19

Clinical Roundup

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Diaceutics has released research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer in the U.S. are still not receiving the most appropriate treatment.

May 01, 2026

Vol.52 No.17

Retifanlimab-dlwr demonstrates 11-month OS difference for anal cancer patients in phase III trial

YOU MAY BE INTERESTED IN

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Perioperative Imfinzi + neoadjuvant EV improved EFS and OS in muscle-invasive bladder cancer, phase III VOLGA trial shows

Phase III trial of sacituzumab tirumotecan met primary endpoints in advanced or recurrent endometrial cancer

Mount Sinai and Cancer Hope Network launch peer support program to help patients navigate treatment, survivorship, and clinical trials

LSU LCMC Health cancer center strengthens cancer clinical trials infrastructure to expand access across Louisiana

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Renew today!

Subscriber content

Never miss an issue!

Login